Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis

@article{Correll2017SafetyOW,
  title={Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis},
  author={Colleen K. Correll and Danielle R. Bullock and Rachel Cafferty and Richard K Vehe},
  journal={Clinical Rheumatology},
  year={2017},
  volume={37},
  pages={549-553}
}
Weekly adalimumab dosing is used to treat juvenile idiopathic arthritis (JIA), uveitis, and other pediatric rheumatic diseases, but the safety of such dosing has not previously been studied. A retrospective chart review was conducted to assess the safety of weekly adalimumab. Demographic and clinical data were collected. Basic descriptive analysis was performed to assess for adverse events from weekly adalimumab. Sixty-nine patients at the University of Minnesota or Gillette Children’s Hospital… Expand
Therapeutic advances in juvenile idiopathic arthritis - associated uveitis
Purpose of review The aim of this review is to highlight recent changes in the treatment of juvenile idiopathic arthritis (JIA) – associated uveitis in the era of biologics. Recent findings EarlyExpand
JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis
TLDR
JAK inhibitors may provide a new valuable treatment option in the therapeutic armamentarium for patients affected with JIA-associated uveitis, particularly in those refractory cases that are not adequately responding to conventional or biologic DMARDs. Expand
Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
TLDR
This is the first pediatric clinical trial to assess the clinical effectiveness and safety of a JAK inhibitor in JIA-uveitis or chronic ANA-positive uveitis, representing a potential novel treatment option for disease management. Expand
Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review
TLDR
Scientific evidence about biologic rescue therapy of JIA-related uveitis in patients who fail to achieve clinical remission, in spite of being treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) and at least one biologic tumor necrosis factor (TNF)-α inhibitor is summarized. Expand
Safety evaluations of adalimumab for childhood chronic rheumatic diseases
TLDR
This review summarizes published knowledge about safety of adalimumab in clinical trials and real-life setting studies and suggests clinical trials coupled with long-term registries will help to improve the evidence-based safety for children with CRD. Expand
Special Considerations: Treatment of Pediatric Uveitis
TLDR
The biologic agents, notably the anti-tumor necrosis factor-alpha inhibitors adalimumab and infliximab, have been increasingly used given their benefit in the control of ocular inflammation. Expand
Epidemiological and advanced therapeutic approaches to treatment of uveitis in pediatric rheumatic diseases: a systematic review and meta-analysis
TLDR
The biologic medications, especially Adalimumab are the most effective treatments for uveitis in pediatric rheumatic diseases; however, a combination of the safe, available alternatives is preferred to achieve the most desirable treatment response. Expand
Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative
TLDR
Recommendations for the diagnosis and treatment of JIA-associated uveitis have been formulated by an evidence-informed consensus process to suggest a standard of care for Jia-associated Uveitis patients throughout Europe. Expand
Update on noninfectious uveitis in children and its treatment.
TLDR
The most important reports in this field that may help to tailor the screening and monitoring of this population in the future and might become the target of novel therapies are described. Expand
Hypersensitivity Reactions to Monoclonal Antibodies in Children
TLDR
The aim of this review is to focus on HSRs associated with the most frequent mAbs in childhood, with particular attention to beta-type reactions. Expand
...
1
2
...

References

SHOWING 1-10 OF 18 REFERENCES
Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry
TLDR
IFX and ADA appear to be effective and safe for treatment of refractory JIA-related uveitis, with a better performance of ADA in the medium-term period. Expand
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed.
TLDR
Among patients with RA for whom previous DMARD treatment had failed, adalimumab monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved physical function and was safe and well tolerated. Expand
Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry
TLDR
Nearly one-half of all children with JIA in the CARRA Registry received biologic DMARD, and their use was strongly associated with RF-positive polyarthritis, PsA, uveitis, and systemic arthritis. Expand
Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn's Disease
TLDR
Weekly adalimumab dosing was clinically beneficial for children with Crohn's disease who experienced nonresponse or flare on EOW dosing and no increased safety risks were observed with weekly dosing. Expand
Demyelinating disorders secondary to TNF-inhibitor therapy for the treatment of psoriasis: A review
TLDR
The results of the present review suggest that demyelinating diseases associated with TNFi are extremely rare, however, with clinical vigilance and individualized treatment regimen, TNFi may be safe for use in other patients. Expand
Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa
TLDR
Adalimumab dosed once per week alleviates moderate to severe HS and significantly greater improvements in patient-reported outcomes and pain were seen in the weekly dosing group than in the placebo group. Expand
Systematic Review of the Toxicity of Long-Course Oral Corticosteroids in Children
TLDR
Weight gain, growth retardation and Cushingoid features were the most frequent ADRs seen when long-course oral corticosteroids were given to children, and increased susceptibility to infection was the most serious ADR. Expand
What is the Background Incidence of Malignancy in Children with Rheumatic Disease?
TLDR
Two studies of the incidence of malignancy associated with juvenile idiopathic arthritis reveal that JIA is likely to be associated with an increased risk of incident malignancies, irrespective of treatment with new biologic agents. Expand
Autoimmune diseases induced by TNF-targeted therapies.
TLDR
The clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in all reports of autoimmune diseases developing after TNF-targeted therapy, were analyzed through a baseline Medline search of articles published between January 1990 and May 2008. Expand
Cost‐effectiveness of biologics in polyarticular‐course juvenile idiopathic arthritis patients unresponsive to disease‐modifying antirheumatic drugs
TLDR
The primary study objective was to determine the incremental costs of biologics per additional responder compared to conventional treatment (methotrexate). Expand
...
1
2
...